Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK DIRECTOR DEALINGS SUMMARY: ASOS CEO Sells GBP20 Million In Shares

Fri, 30th Jan 2015 12:45

Director Dealings Summary - Week Ended January 30        
Company Name Position Buy or Sell Number of Shares Resulting Holding *Note
3i Group Caroline Banszky Non-Executive Director Buy 6,000 undisclosed Same day as dilluted net aset value increased 5%
ASOS Nick Robertson CEO Sold 744,600 7 million Deal worth GBP20 million
Braemar Shipping Jürgen Breuer Non-Executive Director Buy 6,000 6,000 First purchase
Brewin Dolphin Paul Wilson Director Buy 8,596 8,596  
Burberry Carolyn McCall Non-Executive Director Buy 1,117 undisclosed McCall also is CEO of easyJet
Bushveld Minerals Ian Watson Chairman Buy 540,000 undisclosed  
Crest Nicholson Steve Evans Production Director Sold 350,000 307,765 Same day as company reported profit increase
Daily Internet Michael Edelson Chairman Buy 6.3 million 27.6 million  
Daily Internet Christopher Evans CEO Buy 369,485 19.6 million  
Flybe Simon Laffin Chairman Buy 6,728 288,000 Same day as shares hit 14-month low
Foreign & Colonial Investment Trust  Christopher Keljik  Non-Executive Director Buy 9,000 72,001  
IG Group Stephen Hill Non-Executive Director Sold 42,000 79,324 Same day as Ex-dividend date
JPMorgan Smaller Cos Michael Quicke Chairman Buy 4.879 9,212  
JPMorgan Smaller Cos Andrew Robson Non-Executive Director Buy 1,000 2,163  
Learning Technologies Jonathan Satchell CEO Sold 3 million 110.2 million 11 days after saying  FY results to be ahead of expectations
Learning Technologies Leslie-Ann Reed Non-Executive Director Buy 750,000 750,000  
Learning Technologies Neil Elton Non-Executive Director Buy 160,000 160,000  
Kingfisher Ian Cheshire Director Sold 16,000 undisclosed Stood down as CEO on December, 8 2014
Kingfisher Kate Cheshire Spouse Sold 15,000 undisclosed  
Miton Group Gervais Williams MD Buy 295,000 9.1 million  
Porvair Raj Rajagopal Non-Executive Director Buy 15,000 15,000  
Proactis Sean McDonough COO Sold 100,000 121,666 Sold to other directors
Proactis Alan Aubrey Chairman Buy 25,000 1.1 million  
Proactis Rod Jones CEO Buy 25,000 1.9 million  
Proactis Tim Sykes CFO Buy 25,000 148,001  
Proactis Rodney Potts Non-Executive Director Buy 25,000 8.9 million  
ReNeuron Olav Hellebø CEO Buy 322,778 322,778  
ReNeuron Michael Hunt CFO Buy 161,556 1.5 million  
Telecom Plus Charles Wigoder Chairman Buy 25,000 16 million  
Telecom Plus Julian Schild Non-Executive Director Buy 25,000 158,682  
Telecom Plus Melvin Lawson Non-Executive Director Buy 25,000 2.1 million  
WYG Graham Olver COO Sold 23,404 1.9 million share options 2 days after WYG launched review into selling the company
WYG Louise Olver Spouse Sold 64,322 Nil  
             
*Note: A recent company event around the time of the dealing does not suggest the dealing took place because of that event.
When a spouse or related party to a director buys shares, the resulting holding is the beneficial holding of the director
             
Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam    
             
Copyright 2015 Alliance News Limited. All Rights Reserved.        

More News
29 Nov 2019 16:07

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
23 Oct 2019 15:50

ReNeuron presents new data on CTX stem cell platform

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Wednesday that new data relating to its CTX stem cell platform was being presented at the 27th Annual Congress of the European Society of Gene and Cell Therapy in Barcelona.

Read more
23 Oct 2019 09:32

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

Read more
2 Oct 2019 15:15

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

Read more
21 Aug 2019 11:49

ReNeuron boosts scientific advisory board with three appointments

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced the appointment of professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its scientific advisory board on Wednesday.

Read more
14 Aug 2019 15:35

ReNeuron's New Cardiff University Venture Gets Research Grant

(Alliance News) - ReNeuron Group PLC on Wednesday said a new venture with Cardiff University has secured a UK government grant to research and develop new treatments for hard-to-target disorders a

Read more
14 Aug 2019 11:16

ReNeuron enters grant-funded partnership with University of Cardiff

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group is partnering with the University of Cardiff under a new grant-funded collaboration utilising its exosome-based drug delivery technology platform, it announced on Wednesday.

Read more
16 Jul 2019 12:16

ReNeuron Secures Patents For Its Exosome Technology Platform

(Alliance News) - ReNeuron Group PLC on Tuesday said it has expanded its intellectual property estate via the grant of patents, covering its exosome technology platform.The cell-based said

Read more
11 Jul 2019 11:36

ReNeuron Annual Loss Narrows On Finance Income And Licence Fee

(Alliance News) - ReNeuron Group PLC on Thursday said its loss narrowed in its most recent financial year after it received an exclusivity fee and increased finance income.Shares in were at

Read more
14 Jun 2019 15:49

ReNeuron wins 'Breakthrough of the Year' at European Mediscience Awards

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has won the 'Breakthrough of the Year' award at the 2019 European Mediscience Awards, it announced on Friday.

Read more
8 May 2019 11:19

ReNeuron Expects Annual Results In Line With Views After Progress

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday said it expects its annual results to be in line with the board's expectations as it made progress on several clinical cell-based also

Read more
8 May 2019 08:53

ReNeuron advances blindness and stroke therapy candidates

(Sharecast News) - Therapeutics outfit ReNeuron continued to trade in line with expectations throughout its recently wrapped up trading year, advancing both its human retinal progenitor cell therapy candidate and its CTX cell therapy candidate.

Read more
26 Apr 2019 12:09

ReNeuron upbeat on early data from retinitis pigmentosa trials

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced updated positive preliminary data in its ongoing phase 1 and 2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP), on Friday.

Read more
26 Apr 2019 09:58

ReNeuron Reports Positive Test Results For Blindness Treatment Therapy

LONDON (Alliance News) - ReNeuron Group PLC on Friday reported positive trial results for its human retinal progenitor cell therapy candidate for treating blindness-causing disease retinitis in up

Read more
11 Apr 2019 18:24

DIRECTOR DEALINGS: ReNeuron Chair And Other Board Members Buy Shares

LONDON (Alliance News) - ReNeuron Group PLC said a number of directors purchased shares on Thursday, including Non-Executive Chair John Berriman who bought 80,000 shares at 225 pence Thursday, in

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.